Staar Surgical Company (STAA)
NASDAQ:STAA
Want to see STAA full AI Analyst Report?
STAA Stock Chart & Stats
$25.08
-$1.18(-4.94%)
At close: 4:00 PM EST
$25.08
-$1.18(-4.94%)
Day’s Range― - ―
52-Week Range$15.59 - $35.87
Previous CloseN/A
Volume326.32K
Average Volume (3M)987.73K
Market Cap
$1.42B
Enterprise Value$1.39B
Total Cash (Recent Filing)$163.89M
Total Debt (Recent Filing)$37.29M
Price to Earnings (P/E)―
Beta1.07
Next Earnings
Aug 12, 2026EPS Estimate
0.22Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.42
Shares Outstanding49,788,494
10 Day Avg. Volume998,799
30 Day Avg. Volume987,729
Financial Highlights & Ratios
PEG Ratio-0.05
Price to Book (P/B)3.40
Price to Sales (P/S)4.89
P/FCF Ratio-29.21
Enterprise Value/Market Cap0.98
Enterprise Value/Revenue4.80
Enterprise Value/Gross Profit6.28
Enterprise Value/Ebitda94.19
Forecast
1Y Price Target
$29.14Price Target Upside16.20% Upside
Rating ConsensusHold
Number of Analyst Covering9
EPS Forecast (FY)0.65
Revenue Forecast (FY)$331.96M
Bulls Say, Bears Say
Bulls Say
Balance Sheet StrengthVery low leverage and a sizable equity base provide durable financial flexibility. With no meaningful debt and a large cash cushion reported in Q1, the company can fund manufacturing scale, product rollouts and temporary operating losses without near-term refinancing risk, supporting multi-quarter execution.
High And Sustainable Gross MarginsConsistently elevated gross margins reflect strong product economics for implantable lenses. High unit-level margins create room to absorb SG&A or R&D while preserving operating leverage as volumes scale, supporting durable profitability if sales growth persists and mix remains favorable.
Product Leadership & Scalable SupplyA large installed base, successful EVO+ launch and plans to scale Swiss manufacturing reduce tariff exposure and strengthen go-to-market capacity. These structural product and supply milestones support sustained surgeon adoption and geographic expansion over many quarters.
Bears Say
Weak Cash GenerationMaterial negative operating and free cash flow in the trailing twelve months increases execution risk. Continued cash burn could deplete reserves or force spending cuts if revenue momentum weakens, limiting flexibility for marketing, training or manufacturing investments over coming quarters.
China ConcentrationRoughly half of quarterly sales coming from China creates meaningful single-market exposure. Regulatory, geopolitical or demand shifts in that market could cause outsized revenue volatility and undermine the company’s global recovery if China demand or distributor dynamics reverse.
Pricing Pressure & Margin VolatilitySustained ASP declines compress the pathway from revenue growth to durable profits even with high gross margins. Combined with higher-cost inventory roll-through and prior manufacturing headwinds, pricing pressure raises uncertainty around margin sustainability over multiple quarters.
Staar Surgical News
STAA FAQ
What was Staar Surgical Company’s price range in the past 12 months?
Staar Surgical Company lowest stock price was $15.59 and its highest was $35.87 in the past 12 months.
What is Staar Surgical Company’s market cap?
Staar Surgical Company’s market cap is $1.42B.
When is Staar Surgical Company’s upcoming earnings report date?
Staar Surgical Company’s upcoming earnings report date is Aug 12, 2026 which is in 69 days.
How were Staar Surgical Company’s earnings last quarter?
Staar Surgical Company released its earnings results on May 13, 2026. The company reported $0.41 earnings per share for the quarter, beating the consensus estimate of $0.054 by $0.356.
Is Staar Surgical Company overvalued?
According to Wall Street analysts Staar Surgical Company’s price is currently Undervalued.
Does Staar Surgical Company pay dividends?
Staar Surgical Company does not currently pay dividends.
What is Staar Surgical Company’s EPS estimate?
Staar Surgical Company’s EPS estimate is 0.22.
How many shares outstanding does Staar Surgical Company have?
Staar Surgical Company has 49,788,494 shares outstanding.
What happened to Staar Surgical Company’s price movement after its last earnings report?
Staar Surgical Company reported an EPS of $0.41 in its last earnings report, beating expectations of $0.054. Following the earnings report the stock price went up 8.878%.
Which hedge fund is a major shareholder of Staar Surgical Company?
Currently, no hedge funds are holding shares in STAA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Staar Surgical Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$29.14 (16.20% Upside)
$29.14 (16.20% Upside)
Blogger Sentiment
Bullish
STAA Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 574.9K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $12.3M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.3%
Last 30 Days ▼ 9.1%
Last 30 Days ▼ 9.1%
News Sentiment
Bullish
Bullish news 79%
Bearish news 33%
Bearish news 33%
Technicals
SMA
Positive
20 days / 200 days
Momentum
70.70%
12-Months-Change
Fundamentals
Return on Equity
-6.07%
Trailing 12-Months
Asset Growth
-1.37%
Trailing 12-Months
Company Description
Staar Surgical Company
STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and companion delivery systems to deliver the lenses into the eye. The company provides Visian implantable Collamer lens product family (ICLs) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia; and Hyperopic ICL, which treats far-sightedness. It also offers preloaded silicone cataract intraocular lenses and injector systems for use in cataract surgery. In addition, the company sells injector parts, and other related instruments and devices. It markets its products to health care providers, including ophthalmic surgeons, vision and surgical centers, hospitals, government facilities, and distributors, as well as products are primarily used by ophthalmologists. The company sells its products directly through its sales representatives in the United States, Japan, Germany, Spain, Canada, the United Kingdom, and Singapore, as well as through own representatives and independent distributors in China, Korea, India, France, Benelux, Italy, and internationally. STAAR Surgical Company was incorporated in 1982 and is headquartered in Lake Forest, California.
STAA Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed a strong operational and financial turnaround in Q1 2026 highlighted by very strong revenue growth (+119.6% YoY), a return to profitability (adjusted EBITDA $24.4M), improved gross margins (73.6% vs. 65.8%), normalized distributor inventories in China, product launches (EVO+), and scalable Swiss manufacturing to avoid tariffs. Management emphasized cost discipline and a clearer path to sustainable profitability. Offsetting factors include geopolitical and regional headwinds (Middle East, India), near-term pricing pressure (ASP down high single digits), some lingering inventory and higher-cost product roll-through impacts, and conservative disclosure (no formal guidance) due to macro uncertainty and limited near-term visibility. Overall, the positive operational and financial momentum materially outweighs the listed challenges, though dependence on China and macro risks warrant continued monitoring.View all STAA earnings summariesSTAA Stock 12 Month Forecast
Average Price Target
$29.14
▲(16.20% Upside)
Technical Analysis
Ownership Overview
Currently, No data available
---